



CanniMed[®] MEDICAL CANNABIS OIL



1:20

THC 1.0 mg/ml
CBD 20.0 mg/ml

10:10

THC 9.8 mg/ml
CBD 9.9 mg/ml

18:0

THC 18.3 mg/ml
CBD 0.2 mg/ml

OVERVIEW

A specialized product which has virtually no psychotropic effects as a result of its extremely low THC concentration.

With an even ratio of THC and CBD, this CanniMed[®] Oil product is showing efficacy with a wide range of conditions.

This product has the highest level of THC of all the CanniMed[®] Oil products.

DETAILS

Children and other patients sensitive to the effects of THC find value in this product rich in CBD.

CBD is an effective treatment for inflammation, pain, nausea, psychosis, anxiety, ischemia, seizure and has potential for treating children with severe epilepsy.

Patient data shows products like CanniMed[®] 10:10, with moderate levels of both THC and CBD, are used by patients treating a wide range of condition and ailment types.

Recommended in particular for the relief of cancer pain, neuropathic pain and insomnia.

Suitable for patients who have found that CanniMed[®] 10:10 and CanniMed[®] 1:20 do not meet their therapeutic needs.

Recommended for the relief of cancer pain, autoimmune conditions and to treat inflammation.

DOSING

Patients new to cannabis oil should begin their dose at less than 0.5 ml.

60 ml CanniMed[®] Oil is equivalent to 10 g of CanniMed[®] dried cannabis. Health Canada requires physicians to authorize the gram equivalency on medical documents.

Grams per day of dried cannabis	Equivalent ml of Oil	CanniMed [®] Oil 18:0	CanniMed [®] Oil 10:10	CanniMed [®] Oil 1:20
1 gram / day	6 ml	109.8 mg THC / day 1.2 mg CBD / day	58.8 mg THC / day 59.4 mg CBD / day	6.0 mg THC / day 120.0 mg CBD / day
2 gram / day	12 ml	219.6 mg THC / day 2.4 mg CBD / day	117.6 mg THC / day 118.8 mg CBD / day	12.0 mg THC / day 240.0 mg CBD / day
3 gram / day	18 ml	329.4 mg THC / day 3.6 mg CBD / day	176.4 mg THC / day 178.2 mg CBD / day	18.0 mg THC / day 360.0 mg CBD / day

• THC, CBD and other cannabinoids are removed from the plant material and then blended into olive oil.

RECOMMENDATIONS

- CanniMed[®] Oils are for oral use only. Not for the use in a vaporizer.
- It can take from 1 to 1.5 hours before a dose is felt, and peak effect can take up to 4 hours.
- Wait at least 4 hours between doses.

<http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php>

WARNING: OVERCONSUMPTION OF ORAL CANNABIS OIL MAY LEAD TO AN OVERDOSE RESPONSE

1-855-787-1577 • INFO@CANNIMED.COM • CANNIMED.CA

SIDE EFFECTS

The risks of serious side effects from medical cannabis use are low compared to other prescription drugs. However, evaluating safety data has been complicated because of the historically illegal status of cannabis. Listed below are some of the more common and severe side effects observed from cannabis use:

- Drowsiness ^{1, 2, 3, 4}
- Dizziness ^{2, 3, 4}
- Dry mouth ^{1, 2, 4}
- Fatigue ^{5, 6, 7}
- Increased heart rate ⁸
- Postural hypotension ^{3, 9, 10}
- Delayed fetal growth ^{11, 12, 13}
- Excreted in breast milk ^{14, 15, 16}
- Caution driving under the influence ^{17, 18, 19}

WARNINGS

- Pregnant and nursing women should not use medical cannabis – Cannabinoids can affect nervous system development and the growth of the fetus while in the womb
- Cannabis has a potential for dependence and abuse
- Do not drive a vehicle or operate machinery after using cannabis

CAUTION

Physicians may wish to be careful when providing medical cannabis to patients with a history of:

- Cardiac disorder (hypertension, hypotension) ^{20, 21}
- Substance abuse or dependency ^{22, 23, 24}
- Mania or depression ^{22, 25, 26}
- Multiple drug therapy (may be a CYP3A4 or CYP2C9 liver enzyme inhibitor) ^{27, 28}

CONTRAINDICATIONS

Physicians may wish to withhold access to medical cannabis for patients with a history of:

- Hypersensitivity to any cannabinoid
- Psychotic disorders – particularly schizophrenia

1. Lal, S., Prasad, N., Ryan, M., Tangri, S. and others. (2011). Cannabis use amongst patients with inflammatory bowel disease. *Eur.J.Gastroenterol.Hepatol.* 23: 891-896.
2. Toth, C., Mawani, S., Brady, S., Chan, C. and others. (2012). An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. *Pain.* 153: 2073-2082.
3. Machado Rocha, F. C., Stefano, S. C., De Cassia, Haiek R., Rosa Oliveira, L. M. and others. (2008). Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. *Eur.J.Cancer Care (Engl.)*. 17: 431-443.
4. Aragona, M., Onesti, E., Tomassini, V., Conte, A. and others. (2009). Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. *Clin.Neuropharmacol.* 32: 41-47.
5. Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S. and others. (2012). Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *CMAJ.* 184: 1143-1150.
6. Wade, D. T., Makela, P. M., House, H., Bateman, C. and others. (2006). Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. *Mult.Scler.* 12: 639-645.
7. Collin, C., Davies, P., Mutiboko, I. K., and Ratcliffe, S. (2007). Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. *Eur.J.Neurol.* 14: 290-296.
8. Kelly, T. H., Foltin, R. W., and Fischman, M. W. (1993). Effects of smoked marijuana on heart rate, drug ratings and task performance by humans. *Behav.Pharmacol.* 4: 167-178.
9. Fiz, J., Duran, M., Capella, D., Carbonell, J. and others. (2011). Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. *PLoS.One.* 6: e18440.-
10. Sidney, S. (2002). Cardiovascular consequences of marijuana use. *J.Clin.Pharmacol.* 42: 64S-70S.
11. Fried, P. A. (2002). Conceptual issues in behavioral teratology and their application in determining long-term sequelae of prenatal marijuana exposure. *J.Child Psychol.Psychiatry.* 43: 81-102.
12. Richardson, G. A., Ryan, C., Willford, J., Day, N. L. and others. (2002). Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. *Neurotoxicol.Teratol.* 24: 309-320.
13. El-Marroun, H., Tiemeier, H., Steegers, E. A., Jaddoe, V. W and others. (2009). Intrauterine Cannabis Exposure Affects Fetal Growth Trajectories: The Generation R Study. *J.Am.Acad.Child Adolesc.Psychiatry.* 48: 1173-1181.14. Perez-Reyes, M. and Wall, M. E. (1982). Presence of delta9-tetrahydrocannabinol in human milk. *N.Engl.J.Med.* 307: 819-820.

15. Ahmad, G. R. and Ahmad, N. (1990). Passive consumption of marijuana through milk: a low level chronic exposure to delta-9-tetrahydrocannabinol(THC). *J.Toxicol.Clin.Toxicol.* 28: 255-260.
16. Astley, S. J. and Little, R. E. (1990). Maternal marijuana use during lactation and infant development at one year. *Neurotoxicol.Teratol.* 12: 161-168.
17. Asbridge, M., Hayden, J. A., and Cartwright, J. L. (2012). Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. *BMJ.* 344: e536-
18. Bosker, W. M., Kuypers, K. P., Theunissen, E. L., Surinx, A. and others. (2012). Medicinal Delta(9)-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. *Addiction.* 107: 1837-1844.
19. Kuypers, K. P., Legrand, S. A., Ramaekers, J. G., and Verstraete, A. G. (2012). A case-control study estimating accident risk for alcohol, medicines and illegal drugs. *PLoS.One.* 7: e43496-
20. Institute of Medicine. First, do no harm: consequences of marijuana use and abuse. Marijuana and medicine: Assessing the science base. Joy, J. E., Watson, S. J., and Benson, J. A. Washington, DC: National Academy Press, 1999.
21. Mittleman, M. A. and Mostofsky, E. (2011). Physical, psychological and chemical triggers of acute cardiovascular events: preventive strategies. *Circulation.* 124: 346-354.
22. Vandrey, R. and Haney, M. (2009). Pharmacotherapy for cannabis dependence: how close are we? *CNS.Drugs.* 23: 543-553.
23. Hall, W. and Solowij, N. The adverse health and psychological consequences of cannabis dependence. Cannabis dependence. Roffman, R. A. and Stephens, R. S. Cambridge: Cambridge University Press, 2006.
24. Cooper, Z. D. and Haney, M. (2008). Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. *Addict.Biol.* 13: 188-195.
25. van Rossum, I., Boomsma, M., Tenback, D., Reed, C. and others. (2009). Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. *J.Nerv.Ment.Dis.* 197: 35-40.
26. Kuepper, R., van, Os J., Lieb, R., Wittchen, H. U. and others. (2011). Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. *BMJ.* 342: d738.-
27. Yamaori, S., Kushihara, M., Yamamoto, I., and Watanabe, K. (2010). Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. *Biochem.Pharmacol.* 79: 1691-1698.
28. Sachse-Seeboth, C., Pfeil, J., Sehr, D., Meineke, I. and others. (2009). Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. *Clin.Pharmacol.Ther.* 85: 273-276.